Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.36 |
| ▸ | CCND1 | P24385 | 13/20 | 0.36 |
| ▸ | CCND2 | P30279 | 13/20 | 0.36 |
| ▸ | CCND3 | P30281 | 13/20 | 0.36 |
| ▸ | USP1 | O94782 | 6/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 6/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660299 | 0.82 | CDK4 (0.38) | CDK4CCND1CCND2CCND3USP1 | |
| SCHEMBL9988062 | 0.82 | CDK4 (0.37) | CDK4CCND1CCND2CCND3USP1 | |
| SCHEMBL9987988 | 0.80 | CDK4 (0.36) | CDK4CCND1CCND2CCND3USP1 | |
| SCHEMBL5264731 | 0.74 | CDK4 (0.57) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL5265571 | 0.73 | CDK4 (0.57) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL9988786 | 0.73 | CDK4 (0.67) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL2734374 | 0.70 | CDK4 (0.49) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL4835897 | 0.70 | CCND1 (0.47) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL7509063 | 0.69 | CDK4 (0.52) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL24670450 | 0.69 | CDK4 (0.60) | CDK4CCND1CCND2CCND3CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013086451-A2 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086451-A2 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2582374-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Afraxis, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2580213-A2 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | Afraxis, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011159945-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156640-A2 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156640-A2 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | CDK4 408/4885CCND1 3984/4885CCND2 3905/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CCND2 2332/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | CDK4 2822/4885CCND1 4884/4885CCND2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.